Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
Launched by IBN SINA HOSPITAL · Sep 17, 2018
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • ICSI participants
- Exclusion Criteria:
- • -
About Ibn Sina Hospital
Ibn Sina Hospital is a leading healthcare institution dedicated to advancing medical research and patient care through innovative clinical trials. With a commitment to enhancing health outcomes, the hospital collaborates with a diverse range of healthcare professionals and researchers to conduct rigorous studies that adhere to the highest ethical and scientific standards. Its state-of-the-art facilities and multidisciplinary approach enable the exploration of new therapies and treatment modalities, fostering a robust environment for clinical investigation and contributing to the body of medical knowledge. Ibn Sina Hospital is focused on improving patient lives through evidence-based practices and pioneering research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sohag, , Egypt
Assiut, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials